Skip to main content
TipRanks
Go Ultimate75% OFF

Fisher & Paykel Healthcare Corporation Limited (FPH) AI Stock Analysis

3 Followers
NZ:FPH

Fisher & Paykel Healthcare Corporation Limited

(NZX:FPH)

Select Model
Rating:80Outperform
Price Target:NZD 53.00â–²(7.53% Upside)
Action:initiatedcoverage
Date:10/05/26

The score is driven primarily by strong financial performance (high margins, low leverage, improved cash generation) and supportive technical momentum (price above key moving averages, positive MACD). Offsetting factors are expensive valuation (very high P/E with modest yield) and FY27 execution/macro risks flagged on the earnings call (tariffs, surcharges, FX sensitivity, and potential hardware growth normalization).

Positive Factors
Recurring consumables modelRecurring-use consumables create replenishment demand alongside installed equipment, supporting revenue visibility beyond individual hardware purchases. Hospital patient volumes and ongoing homecare replacement needs can help sustain customer relationships, repeat sales, and cash generation over multiple periods.
Negative Factors
Tariffs and logistics cost pressureTariffs and freight-related surcharges directly pressure gross margin and may persist through FY27, making earnings more dependent on continuous-improvement savings. If policy or logistics costs worsen, the company could face sustained profitability pressure or need to adjust pricing and sourcing.

Fisher & Paykel Healthcare Corporation Limited (FPH) vs. SPDR S&P 500 ETF (SPY)

-20%-10%0%10%20%30%40%NZ:FPH+36.48%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
NZD 15.88B
Dividend Yield
1.24%
Average Volume (3M)
537.80K
Price to Earnings (P/E)
61.6
Beta (1Y)
1.67
Revenue Growth
15.59%
EPS Growth
23.94%
Country
NZ
Employees
7,396
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

Fisher & Paykel Healthcare Corporation Limited Business Overview & Revenue Model

Company Description

Operating globally, Fisher & Paykel Healthcare Corporation Limited specializes in the development, manufacturing, and marketing of a wide array of medical device products and systems. These solutions are primarily utilized for acute and chronic respi...

How the Company Makes Money

FPH primarily makes money by selling medical devices and recurring-use consumables used in respiratory support and sleep apnea therapy. A significant portion of revenue is typically driven by ongoing demand for single-patient-use or regularly replace...

Fisher & Paykel Healthcare Corporation Limited Earnings Call Summary

Earnings Call Date:May 25, 2026(Q4-2026)|% Change Since:47.93%|Next Earnings Date:Nov 25, 2026
Earnings Call SentimentPositive

The earnings call conveyed a predominantly positive operational and financial performance: strong top-line growth, substantial NPAT expansion, margin improvement, robust cash flow, higher dividends and continued investment in capacity and R&D. The company provided constructive FY'27 guidance but also clearly articulated material near-term headwinds — notably U.S. tariffs, surcharges from the Middle East conflict, FX/hedging losses, and the risk of hardware growth normalizing after an exceptional year. Management stressed that continuous improvement and manufacturing/network flexibility should offset many of these pressures, but several macro and policy risks remain.

Positive Updates

Strong Revenue Growth
Operating revenue of $2.3 billion, up 14% on prior year (12% in constant currency). FY'27 guidance: $2.45–$2.57 billion (approx. 6%–11% growth).

Negative Updates

Tariff-Related Margin Headwind
U.S. tariffs on NZ-sourced products negatively impacted gross margin by ~90 basis points in FY'26. FY'27 guidance assumes a 10% tariff on certain NZ respiratory products for the full year, estimated to adversely impact gross margin by ~70 basis points (although this is 20 bps better year-on-year).

Company Guidance

Management guided FY27 operating revenue of NZ$2.45–2.57 billion (implying ~6–11% growth, midpoint ≈9%) and net profit after tax of about NZ$500–550 million, built on assumptions including a 10% U.S. tariff on certain New‑Zealand‑made respiratory products for the full year (estimated ~70 basis‑point adverse gross‑margin impact, ~20 bps improvement versus FY26), continued Middle East‑related surcharges of ~45 bps (raw materials) and ~25 bps (freight) (netting to ~50 bps negative to gross margin year‑on‑year after tariff movement) that management expects to more than be offset by continuous‑improvement savings; FY27 capital expenditure is expected at ~NZ$230 million (including ~NZ$125m on land and buildings), operating expenses (R&D and SG&A) are guided to mid‑ to high‑single‑digit growth (R&D was NZ$235.5m, 10% of revenue in FY26), and management highlighted FX and air‑freight as risks (FY26 hedging losses ~$21m pretax; end‑April FY27 hedging loss estimate ~$17m and ~$1m translation loss; ~NZ$2–3m NPAT sensitivity per 1% currency move).

Fisher & Paykel Healthcare Corporation Limited Financial Statement Overview

Summary

Strong overall fundamentals: high and improving profitability (≈64% gross, ≈29% operating, ≈20% net margin), conservative balance sheet with very low leverage, and strengthened cash generation (operating cash flow ≈663M; free cash flow ≈490M). Main constraint on the score is historical variability—profitability and free cash flow were notably weaker/uneven in 2022–2024 before rebounding.

Income Statement

86Very Positive

Balance Sheet

92Very Positive

Cash Flow

84Very Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue2.34B2.34B1.87B1.61B1.48B1.52B
Gross Profit1.50B1.50B1.18B971.56M881.22M936.67M
EBITDA816.70M825.60M611.44M347.08M410.81M566.55M
Net Income468.50M468.50M349.03M121.57M233.18M348.36M
Balance Sheet
Total Assets2.85B2.85B2.36B2.28B2.20B2.11B
Cash, Cash Equivalents and Short-Term Investments461.10M461.10M244.74M82.00M121.00M289.90M
Total Debt146.10M146.10M141.85M189.10M145.80M104.30M
Total Liabilities738.20M738.20M611.07M522.60M451.10M427.30M
Stockholders Equity2.12B2.12B1.75B1.76B1.75B1.68B
Cash Flow
Free Cash Flow490.40M490.40M439.52M90.60M26.90M154.50M
Operating Cash Flow663.20M663.20M507.63M429.60M238.20M324.30M
Investing Cash Flow-195.20M-195.20M-95.31M-339.00M-11.30M-89.50M
Financing Cash Flow-276.70M-276.70M-248.17M-128.70M-197.10M-235.80M

Fisher & Paykel Healthcare Corporation Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price49.29

Price Trends

50DMA47.06Positive
100DMA44.50Positive
200DMA40.85Positive

Market Momentum

MACD0.51Negative
RSI63.94Neutral
STOCH86.44Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NZ:FPH, the sentiment is Positive. The current price of 49.29 is above the 20-day moving average (MA) of 48.10, above the 50-day MA of 47.06, and above the 200-day MA of 40.85, indicating a bullish trend. The MACD of 0.51 indicates Negative momentum. The RSI at 63.94 is Neutral, neither overbought nor oversold. The STOCH value of 86.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NZ:FPH.

Fisher & Paykel Healthcare Corporation Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

NZ:FPH against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
NZ:FPHNZ:FPH80OutperformNZD 29.00B61.6122.84%1.24%15.59%23.94%
NZ:EBONZ:EBO60NeutralNZD 4.53B16.717.99%5.69%16.36%5.52%
NZ:RYMNZ:RYM56NeutralNZD 1.86B-11.12-4.17%―11.86%72.99%
NZ:AFTNZ:AFT54NeutralNZD 481.37M32.4614.07%0.64%22.44%23.14%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NZ:PEBNZ:PEB42NeutralNZD 316.68M-6.66-190.54%―-47.36%-3.79%
NZ:TRUNZ:TRU37UnderperformNZD 8.38M-2.58-75.57%―42.20%23.68%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%NZ:FPHNZ:EBONZ:PEBNZ:RYMNZ:TRUNZ:AFTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
NZ:FPH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
NZ:FPHFisher & Paykel Healthcare Corporation Limited49.2912.5734.25%
NZ:EBOEBOS Group Limited21.65-5.75-20.98%
NZ:PEBPacific Edge Limited0.260.0740.88%
NZ:RYMRyman Healthcare 1.83-1.06-36.66%
NZ:TRUTruScreen Group Ltd.0.01-0.01-41.18%
NZ:AFTAFT Pharmaceuticals Ltd.4.590.9325.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 05, 2026